免疫療法におけるフェノタイプおよび標的薬の発見:課題,機会,および将来の方向
Nelson García Vázquez1, Hossam Nada1, Saurabh Upadhyay1
1Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine New York NY 10065 USA mog4005@med.cornell.edu.
RSC advances
|August 27, 2025
まとめ
この研究は 免疫療法開発を調査し,フェノタイプの薬と標的ベースの薬の発見を組み合わせることで 革新が加速される方法を示しています AIとマルチオミクスを用いた統合的なアプローチは 癌や自己免疫疾患の より効果的な治療法を作るための鍵です
科学分野:
- 免疫学と薬理学
- 薬の発見と開発
背景:
- 免疫療法が医学を 変えてきました 特に癌や自己免疫疾患は
- 伝統的な薬の発見は,表型スクリーニングとターゲットベースのアプローチに依存しています.
- フェノタイプのスクリーニングは新しい治療法を生み出し,ターゲットベースの方法は精度の合理的な設計を可能にします.
研究 の 目的:
- フェノタイプおよびターゲットベースの薬剤発見戦略の進化と統合をレビューする.
- 重要な免疫調節薬とその発見の経路を強調する
- 治療開発を加速するための新興ハイブリッドアプローチを検証する.
主な方法:
- 主要な免疫調節薬 (免疫チェックポイント阻害剤,双特定抗体,小分子調節剤) のレビュー
- 発見経路と作用メカニズムの分析
- 統合コンピューティング,AI,マルチオミクス技術の検討.
主要な成果:
- フェノタイプのスクリーニングにより クラス一の治療法が見つかりました
- 標的型アプローチは 分子メカニズムに基づく 精密薬の設計を可能にします
- コンピューティング・モデリング,AI,マルチオミクスにおける進歩は,両方の戦略の統合を加速しています.
結論:
- フェノタイプとターゲットベースのアプローチの統合は 薬剤発見のパイプラインを再構成しています
- 機能的な洞察と 機械的な洞察を結びつけるハイブリッドのアプローチは 開発を加速するために不可欠です
- 未来の免疫薬の発見には 適応的で統合されたワークフローが必要で 効果を高め 耐性を克服します
さらに関連する動画
関連する概念動画
Microorganisms in Medicine and Therapeutics
314
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
314
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K


